Literature DB >> 19273114

SH2 domain binding to phosphopeptide ligands: potential for drug targeting.

Moses M Kasembeli1, Xuejun Xu, David J Tweardy.   

Abstract

SH2 domains are modular components of a wide range of functionally diverse proteins involved in mammalian signal transduction including enzymes, adaptors, regulators and transcription factors. Members of the SH2 domain family recognize a wide variety of short tyrosine phosphorylated peptide motifs. Biochemical and structural studies have revealed key aspects of these interactions that account for their ability to discriminate between different sequence motifs. While the mechanism of phosphotyrosine (pTyr) recognition is remarkably conserved among the SH2 domains, differences in recognition of phosphopeptide residues N and especially C-terminal to the pTyr have been identified that contribute to selectivity. The basis for SH2- phosphopeptide recognition is discussed in light of the available structural and biochemical data with a focus on recent information regarding SH2 domains within a new class found within the signal transducer and activator of transcription (STAT) protein family.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273114     DOI: 10.2741/3292

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  6 in total

1.  Loops govern SH2 domain specificity by controlling access to binding pockets.

Authors:  Tomonori Kaneko; Haiming Huang; Bing Zhao; Lei Li; Huadong Liu; Courtney K Voss; Chenggang Wu; Martin R Schiller; Shawn Shun-Cheng Li
Journal:  Sci Signal       Date:  2010-05-04       Impact factor: 8.192

2.  Structure of a novel phosphotyrosine-binding domain in Hakai that targets E-cadherin.

Authors:  Manjeet Mukherjee; Soah Yee Chow; Permeen Yusoff; J Seetharaman; Cherlyn Ng; Saravanan Sinniah; Xiao Woon Koh; Nur Farehan M Asgar; Dan Li; Daniel Yim; Rebecca A Jackson; Jingxi Yew; Jingru Qian; Audrey Iyu; Yoon Pin Lim; Xingding Zhou; Siu Kwan Sze; Graeme R Guy; J Sivaraman
Journal:  EMBO J       Date:  2012-01-17       Impact factor: 11.598

3.  DRUGGING "UNDRUGGABLE" DISEASE-CAUSING PROTEINS: FOCUS ON SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) 3.

Authors:  David J Tweardy
Journal:  Trans Am Clin Climatol Assoc       Date:  2022

4.  STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.

Authors:  Mesias Pedroza; Thuy T Le; Katherine Lewis; Harry Karmouty-Quintana; Sarah To; Anuh T George; Michael R Blackburn; David J Tweardy; Sandeep K Agarwal
Journal:  FASEB J       Date:  2015-08-31       Impact factor: 5.191

Review 5.  Histone acetyltransferases: Rising ancient counterparts to protein kinases.

Authors:  Hua Yuan; Ronen Marmorstein
Journal:  Biopolymers       Date:  2013-02       Impact factor: 2.505

6.  Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility.

Authors:  Ren Kong; Uddalak Bharadwaj; T Kris Eckols; Mikhail Kolosov; Haoyi Wu; Francisco J Santa Cruz-Pavlovich; Alison Shaw; Oluwatomilona I Ifelayo; Hong Zhao; Moses M Kasembeli; Stephen T C Wong; David J Tweardy
Journal:  Pharmacol Res       Date:  2021-04-29       Impact factor: 10.334

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.